DongKoo Bio & Pharma Co. Ltd. (006620) — Cash Flow Reinvestment Rate
DongKoo Bio & Pharma Co. Ltd. (006620) has a Cash Flow Reinvestment Rate of 2.51x as of June 2026, reinvesting ₩11.16 Billion (capex ₩5.21 Billion plus investments ₩5.95 Billion) from operating cash flow of ₩4.46 Billion. See 006620 FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
DongKoo Bio & Pharma Co. Ltd. Cash Flow Reinvestment Rate (2015–2024)
Historical reinvestment intensity for DongKoo Bio & Pharma Co. Ltd. across 9 annual periods. For the full cash flow conversion analysis, see DongKoo Bio & Pharma Co. Ltd. (006620) cash conversion ratio.
Annual Cash Flow Reinvestment Rate for DongKoo Bio & Pharma Co. Ltd. (2015–2024)
Year-by-year capital reinvestment analysis for DongKoo Bio & Pharma Co. Ltd.. See how financially flexible is DongKoo Bio & Pharma Co. Ltd. to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (KRW) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2024 | 4.06x | ₩70.50 Billion | ₩17.34 Billion | ₩25.46 Billion | ▼ -30.9% |
| 2023 | 5.88x | ₩21.10 Billion | ₩3.59 Billion | ₩15.97 Billion | ▲ +159.8% |
| 2022 | 2.26x | ₩38.09 Billion | ₩16.82 Billion | ₩11.08 Billion | ▲ +287.3% |
| 2021 | 0.58x | ₩10.47 Billion | ₩17.90 Billion | ₩4.27 Billion | ▼ -61.4% |
| 2020 | 1.51x | ₩11.34 Billion | ₩7.49 Billion | ₩5.27 Billion | ▼ -24.7% |
| 2019 | 2.01x | ₩20.38 Billion | ₩10.14 Billion | ₩8.77 Billion | ▲ +972.5% |
| 2017 | 0.19x | ₩1.78 Billion | ₩9.51 Billion | ₩810.51 Million | ▼ -68.7% |
| 2016 | 0.60x | ₩7.54 Billion | ₩12.59 Billion | ₩6.55 Billion | ▲ +12.0% |
| 2015 | 0.53x | ₩3.71 Billion | ₩6.93 Billion | ₩2.32 Billion | — |